2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II

- Gustafsson, Finn, Petrie, Mark C., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G. F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Komtebedde, Jan, Solomon, Scott D., Shah, SJ, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L.

Association of Circulating Plasma Secreted Frizzled-Related Protein 5 (Sfrp5) Levels with Cardiac Function

- Kelly, Conagh J., Chu, Matthew, Untaru, Rossana, Assadi-Khansari, Bahador, Chen, Dongqing, Croft, Amanda J., Horowitz, John D., Boyle, Andrew J., Sverdlov, Aaron L., Ngo, Doan T. M.

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

- Shah, Sanjiv J., Borlaug, Barry A., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Chung, Eugene S., Leon, Martin B., REDUCE LAP-HF II investigators,, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter S., Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M.

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

- Lyon, Alexander R., Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid J., Groarke, John D., Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Sverdlov, Aaron L.

Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?

- Balachandran, Lohis, Haw, Tatt Jhong, Leong, Angeline Jia Wen, Croft, Amanda J., Chen, Dongqing, Kelly, Conagh, Sverdlov, Aaron L., Ngo, Doan T. M.